These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38880868)

  • 21. Vaccination with outer membrane vesicles from Neisseria Meningitidis and SBa15, SBa16 mesoporous silica associated with SARS-CoV-2 induces protective humoral and cellular response against COVID-19 in mice.
    Bernardes BG; Moura AD; Guarnieri JPO; Silva CFMD; Costa HHMD; Silva IGMD; Cordeiro KBB; Báo SN; Prudêncio CR; Lancellotti M
    Braz J Infect Dis; 2024; 28(6):104479. PubMed ID: 39547005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals.
    Aljehani ND; Tamming L; Khan MY; Abdulal RH; Alfaleh MA; Ghazwani A; Helal A; Alsulaiman RM; Sanki MA; Alluhaybi K; Sukareh FA; Alharbi RH; Alyami FH; ElAssouli M-Z; Shebbo S; Abdulaal WH; Algaissi A; Mahmoud AB; Basabrain M; Duque D; Bavananthasivam J; Chen W; Wang L; Sauve S; Abujamel TS; Altorki T; Alhabbab R; Tran A; Li X; Hashem AM
    mBio; 2024 Dec; ():e0217024. PubMed ID: 39629990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting.
    Seow J; Jefferson GCE; Keegan MD; Yau Y; Snell LB; Doores KJ
    PLoS Pathog; 2024 Nov; 20(11):e1012724. PubMed ID: 39556615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo.
    Tsugawa Y; Furukawa K; Ise T; Takayama M; Ota T; Kuroda T; Shano S; Hashimoto T; Konishi H; Ishihara T; Sato M; Kamada H; Fukao K; Shishido T; Yoshikawa M; Takahashi T; Nagata S
    PLoS One; 2024; 19(12):e0300297. PubMed ID: 39621673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody dynamics for heterologous boosters with aerosolized Ad5-nCoV following inactivated COVID-19 vaccines.
    Chen C; Tang T; Chen Z; Chen L; Cheng J; Li F; Sun J; Zhao J; Wang Y; Yan Q; Zhao J; Zhu A
    Hum Vaccin Immunother; 2024 Dec; 20(1):2423466. PubMed ID: 39535117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study.
    Rizvi NB; Bibi M; Rana MZ; Zaffar S; Farooq H
    Front Immunol; 2024; 15():1448408. PubMed ID: 39606247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses.
    Padilla-Bórquez DL; Matuz-Flores MG; Hernández-Bello J; Rosas-Rodríguez JA; Turrubiates-Hernández FJ; García-Arellano S; González-Estevez G; Ceja-Galvez HR; Oregon-Romero E; López-Reyes A; Muñoz-Valle JF
    Hum Vaccin Immunother; 2024 Dec; 20(1):2394265. PubMed ID: 39246041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody response to SARS-CoV-2 mRNA vaccination in Danish adults exposed to perfluoroalkyl substances (PFASs): The ENFORCE study.
    Timmermann A; Johansen IS; Tolstrup M; Heilmann C; Budtz-Jørgensen E; Tolstrup JS; Nielsen F; Grandjean P
    Environ Res; 2024 Dec; 263(Pt 1):120039. PubMed ID: 39326653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial.
    Naficy A; Kuxhausen A; Seifert H; Hastie A; Leav B; Miller J; Anteyi K; Mwakingwe-Omari A
    Hum Vaccin Immunother; 2024 Dec; 20(1):2327736. PubMed ID: 38513689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein.
    Mendoza-Ramírez NJ; García-Cordero J; Shrivastava G; Cedillo-Barrón L
    J Immunol Res; 2024; 2024():9313267. PubMed ID: 38939745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of T cell response against XBB variants in adults who received either monovalent wild-type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster.
    Tang YS; Tan CW; Chong KC; Chen C; Sun Y; Yiu K; Ling KC; Chan KKP; Peiris M; Mok CKP; Hui DS
    Int J Infect Dis; 2024 Dec; 149():107271. PubMed ID: 39426493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel HBc-S230 protein chimeric VLPs induced robust immune responses against SARS-CoV-2.
    Feng W; Chen Z; Wu L; Chen X; Li Q; Xiang Y; Guo Y; Du W; Chen J; Zhu S; Dong H; Xue X; Zhao KN; Zhang L
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113362. PubMed ID: 39426233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY.
    Pearce FA; Lim SH; Bythell M; Lanyon P; Hogg R; Taylor A; Powter G; Cooke GS; Ward H; Chilcot J; Thomas H; Mumford L; McAdoo SP; Pettigrew GJ; Lightstone L; Willicombe M
    Lancet Rheumatol; 2023 Aug; 5(8):e461-e473. PubMed ID: 38251578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome.
    Nouwen AEM; Zaeck LM; Schappin R; Geers D; Gommers L; Bogers S; Dik WA; Pasmans SGMA; GeurtsvanKessel CH; de Vries RD; Dalm VASH
    J Clin Immunol; 2024 Oct; 45(1):36. PubMed ID: 39476295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Qualitative evidence synthesis informing our understanding of people's perceptions and experiences of targeted digital communication.
    Ryan R; Hill S
    Cochrane Database Syst Rev; 2019 Oct; 10(10):ED000141. PubMed ID: 31643081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual-antigen fusion protein vaccination induces protective immunity against
    Jia K; Zhang Y; Jiang M; Cui M; Wang J; Zhang J; Wang H; Zhao H; Li M; Zou Q; Zeng H
    Hum Vaccin Immunother; 2024 Dec; 20(1):2406065. PubMed ID: 39327639
    [No Abstract]   [Full Text] [Related]  

  • 37. Severe acute respiratory syndrome coronavirus 2-specific T-cell responses are induced in people living with human immunodeficiency virus after booster vaccination.
    Wang X; Li Y; Jin J; Chai X; Ma Z; Duan J; Zhang G; Huang T; Zhang X; Zhang T; Wu H; Cao Y; Su B
    Chin Med J (Engl); 2024 Nov; 137(22):2734-2744. PubMed ID: 39028115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
    Alter G; Yu J; Liu J; Chandrashekar A; Borducchi EN; Tostanoski LH; McMahan K; Jacob-Dolan C; Martinez DR; Chang A; Anioke T; Lifton M; Nkolola J; Stephenson KE; Atyeo C; Shin S; Fields P; Kaplan I; Robins H; Amanat F; Krammer F; Baric RS; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H; Barouch DH
    Nature; 2021 Aug; 596(7871):268-272. PubMed ID: 34107529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial.
    Jin P; Liu Q; Chen W; Guo X; Jiang H; Zhang R; Ding M; Zhang K; Cao Z; He J; Jia S; Wei M; Hu Y; Cui L; Wang J; Li Z; Zhang X; Xia X; Wu Y; Zhou L; Zhu Y; Gao C; Zhang T; Zhu F; Zeng G; Zhu L; Li J
    Expert Rev Vaccines; 2024; 23(1):1041-1051. PubMed ID: 39523878
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.